mouse genome Search Results


96
TaKaRa mouse genomic dna
Mouse Genomic Dna, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse genomic dna/product/TaKaRa
Average 96 stars, based on 1 article reviews
mouse genomic dna - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

97
Genecopoeia genome taler mouse rosa26 safe harbor gene knock in kit
Genome Taler Mouse Rosa26 Safe Harbor Gene Knock In Kit, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genome taler mouse rosa26 safe harbor gene knock in kit/product/Genecopoeia
Average 97 stars, based on 1 article reviews
genome taler mouse rosa26 safe harbor gene knock in kit - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

94
Addgene inc knockout crispr library v2
( A ) Experimental design. X-GFP iCas9 ESCs were infected with a genome-wide lentiviral gRNA library and differentiated into NPCs. Next, NPCs were treated with doxycycline to activate the expression of the reprogramming cassette and the iCas9 . The knockouts took place during reprogramming. At day 10 of reprogramming, three populations were FACS-separated: non-pluripotent (SSEA1-X-GFP-), early pluripotent (SSEA1+ X-GFP-) and late pluripotent, X-reactivated (SSEA1+ X-GFP+). For these three populations and the NPCs, genomic DNA extraction, PCR-amplification of the gRNA sequences, sequencing and analysis of gRNA abundance were performed. n=2 biological replicates (independent reprogramming rounds). ( B ) Pathways related to overrepresented genes in the three reprogramming populations (non-pluripotent, early pluripotent and late pluripotent) compared to NPCs (WikiPathways Mouse 2019). For pathway enrichment analysis, the top 250 genes from each individual comparison to NPCs ranked by RRA score with MAGeCK software were merged and selected. ( C ) gRNA abundance comparison (early pluripotent vs non-pluripotent) and representation of genes with negative Log2FC (underrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = −0.75) (activators of early pluripotency). ( D ) gRNA abundance comparison (late pluripotent vs early pluripotent) and representation of genes with negative Log2FC (underrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = −0.75) (activators of late pluripotency, X-reactivation). Genes highlighted in yellow are related to pluripotency, genes highlighted in red are involved in Notch or interferon γ signaling. ( E ) Pathways (WikiPathways Mouse 2019) related to underrepresented genes in “late pluripotent vs early pluripotent” comparison (activators of late pluripotency, X-reactivation, n=1313 genes). Pathways related to proliferation, differentiation and metabolism are shown in gray. The rest of the pathways are highlighted in green. RRA score < 0.05 and Log2FC < −0.8 filtering was applied. ( F ) Experimental design for (G). Treatment with molecules targeting pathways identified in the <t>CRISPR</t> screen was done at the beginning of reprogramming (day 0 - day 5), later in reprogramming (day 5 - day 7) or during the whole process (day 0 - day 7). At day 7, flow cytometry analysis of SSEA1 and X-GFP percentages was performed. ( G ) Pathway validation by molecule treatment at the beginning of reprogramming (day 0 - day 5), later in reprogramming (day 5 - day 7) or during the whole process (day 0 - day 7) in three independent reprogramming rounds, n=3 (except for TGFβ, n=2). Flow cytometry analysis at day 7 of SSEA1 and X-GFP percentages is shown. Data represented as mean +/− SD. Statistics (paired t-tests): where not specified = non-significant; * = p<0.05; ** = p<0.01; *** = p<0.001.
Knockout Crispr Library V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/knockout crispr library v2/product/Addgene inc
Average 94 stars, based on 1 article reviews
knockout crispr library v2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Addgene inc mouse lentiviral crispr guide rna library v2
Mouse embryonic fibroblasts (MEF) stably expressing Flag-Cas9-EGFP were transduced with a <t>lentiviral</t> <t>CRISPR-library.</t> Cells were treated three times with PMT(C1165S)DTa and surviving cells grown. Genomic DNA was extracted, inserted sgRNA amplified and sequenced.
Mouse Lentiviral Crispr Guide Rna Library V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse lentiviral crispr guide rna library v2/product/Addgene inc
Average 93 stars, based on 1 article reviews
mouse lentiviral crispr guide rna library v2 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Addgene inc mouse genome
Mouse embryonic fibroblasts (MEF) stably expressing Flag-Cas9-EGFP were transduced with a <t>lentiviral</t> <t>CRISPR-library.</t> Cells were treated three times with PMT(C1165S)DTa and surviving cells grown. Genomic DNA was extracted, inserted sgRNA amplified and sequenced.
Mouse Genome, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse genome/product/Addgene inc
Average 94 stars, based on 1 article reviews
mouse genome - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
Addgene inc library pmscv u6grna lib pgkpurot2abfp
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
Library Pmscv U6grna Lib Pgkpurot2abfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/library pmscv u6grna lib pgkpurot2abfp/product/Addgene inc
Average 92 stars, based on 1 article reviews
library pmscv u6grna lib pgkpurot2abfp - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

92
Addgene inc mcrispra v2 library
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
Mcrispra V2 Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mcrispra v2 library/product/Addgene inc
Average 92 stars, based on 1 article reviews
mcrispra v2 library - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

91
BioChain Institute 160 copies mouse lung rna
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
160 Copies Mouse Lung Rna, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/160 copies mouse lung rna/product/BioChain Institute
Average 91 stars, based on 1 article reviews
160 copies mouse lung rna - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

86
AMS Biotechnology mouse tissues
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
Mouse Tissues, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse tissues/product/AMS Biotechnology
Average 86 stars, based on 1 article reviews
mouse tissues - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

90
10X Genomics v(d)j enrichment kit for mouse t cells
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
V(D)J Enrichment Kit For Mouse T Cells, supplied by 10X Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/v(d)j enrichment kit for mouse t cells/product/10X Genomics
Average 90 stars, based on 1 article reviews
v(d)j enrichment kit for mouse t cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Genome Systems Inc bac clone containing mouse gli3 genomic dna sequences
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
Bac Clone Containing Mouse Gli3 Genomic Dna Sequences, supplied by Genome Systems Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bac clone containing mouse gli3 genomic dna sequences/product/Genome Systems Inc
Average 90 stars, based on 1 article reviews
bac clone containing mouse gli3 genomic dna sequences - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Illumina Inc whole-genome beadchip sentrix mouse wg-6 v2 array
CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy
Whole Genome Beadchip Sentrix Mouse Wg 6 V2 Array, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/whole-genome beadchip sentrix mouse wg-6 v2 array/product/Illumina Inc
Average 90 stars, based on 1 article reviews
whole-genome beadchip sentrix mouse wg-6 v2 array - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Experimental design. X-GFP iCas9 ESCs were infected with a genome-wide lentiviral gRNA library and differentiated into NPCs. Next, NPCs were treated with doxycycline to activate the expression of the reprogramming cassette and the iCas9 . The knockouts took place during reprogramming. At day 10 of reprogramming, three populations were FACS-separated: non-pluripotent (SSEA1-X-GFP-), early pluripotent (SSEA1+ X-GFP-) and late pluripotent, X-reactivated (SSEA1+ X-GFP+). For these three populations and the NPCs, genomic DNA extraction, PCR-amplification of the gRNA sequences, sequencing and analysis of gRNA abundance were performed. n=2 biological replicates (independent reprogramming rounds). ( B ) Pathways related to overrepresented genes in the three reprogramming populations (non-pluripotent, early pluripotent and late pluripotent) compared to NPCs (WikiPathways Mouse 2019). For pathway enrichment analysis, the top 250 genes from each individual comparison to NPCs ranked by RRA score with MAGeCK software were merged and selected. ( C ) gRNA abundance comparison (early pluripotent vs non-pluripotent) and representation of genes with negative Log2FC (underrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = −0.75) (activators of early pluripotency). ( D ) gRNA abundance comparison (late pluripotent vs early pluripotent) and representation of genes with negative Log2FC (underrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = −0.75) (activators of late pluripotency, X-reactivation). Genes highlighted in yellow are related to pluripotency, genes highlighted in red are involved in Notch or interferon γ signaling. ( E ) Pathways (WikiPathways Mouse 2019) related to underrepresented genes in “late pluripotent vs early pluripotent” comparison (activators of late pluripotency, X-reactivation, n=1313 genes). Pathways related to proliferation, differentiation and metabolism are shown in gray. The rest of the pathways are highlighted in green. RRA score < 0.05 and Log2FC < −0.8 filtering was applied. ( F ) Experimental design for (G). Treatment with molecules targeting pathways identified in the CRISPR screen was done at the beginning of reprogramming (day 0 - day 5), later in reprogramming (day 5 - day 7) or during the whole process (day 0 - day 7). At day 7, flow cytometry analysis of SSEA1 and X-GFP percentages was performed. ( G ) Pathway validation by molecule treatment at the beginning of reprogramming (day 0 - day 5), later in reprogramming (day 5 - day 7) or during the whole process (day 0 - day 7) in three independent reprogramming rounds, n=3 (except for TGFβ, n=2). Flow cytometry analysis at day 7 of SSEA1 and X-GFP percentages is shown. Data represented as mean +/− SD. Statistics (paired t-tests): where not specified = non-significant; * = p<0.05; ** = p<0.01; *** = p<0.001.

Journal: bioRxiv

Article Title: The Interferon γ Pathway Enhances Pluripotency and X-Chromosome Reactivation in iPSC reprogramming

doi: 10.1101/2023.07.31.551297

Figure Lengend Snippet: ( A ) Experimental design. X-GFP iCas9 ESCs were infected with a genome-wide lentiviral gRNA library and differentiated into NPCs. Next, NPCs were treated with doxycycline to activate the expression of the reprogramming cassette and the iCas9 . The knockouts took place during reprogramming. At day 10 of reprogramming, three populations were FACS-separated: non-pluripotent (SSEA1-X-GFP-), early pluripotent (SSEA1+ X-GFP-) and late pluripotent, X-reactivated (SSEA1+ X-GFP+). For these three populations and the NPCs, genomic DNA extraction, PCR-amplification of the gRNA sequences, sequencing and analysis of gRNA abundance were performed. n=2 biological replicates (independent reprogramming rounds). ( B ) Pathways related to overrepresented genes in the three reprogramming populations (non-pluripotent, early pluripotent and late pluripotent) compared to NPCs (WikiPathways Mouse 2019). For pathway enrichment analysis, the top 250 genes from each individual comparison to NPCs ranked by RRA score with MAGeCK software were merged and selected. ( C ) gRNA abundance comparison (early pluripotent vs non-pluripotent) and representation of genes with negative Log2FC (underrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = −0.75) (activators of early pluripotency). ( D ) gRNA abundance comparison (late pluripotent vs early pluripotent) and representation of genes with negative Log2FC (underrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = −0.75) (activators of late pluripotency, X-reactivation). Genes highlighted in yellow are related to pluripotency, genes highlighted in red are involved in Notch or interferon γ signaling. ( E ) Pathways (WikiPathways Mouse 2019) related to underrepresented genes in “late pluripotent vs early pluripotent” comparison (activators of late pluripotency, X-reactivation, n=1313 genes). Pathways related to proliferation, differentiation and metabolism are shown in gray. The rest of the pathways are highlighted in green. RRA score < 0.05 and Log2FC < −0.8 filtering was applied. ( F ) Experimental design for (G). Treatment with molecules targeting pathways identified in the CRISPR screen was done at the beginning of reprogramming (day 0 - day 5), later in reprogramming (day 5 - day 7) or during the whole process (day 0 - day 7). At day 7, flow cytometry analysis of SSEA1 and X-GFP percentages was performed. ( G ) Pathway validation by molecule treatment at the beginning of reprogramming (day 0 - day 5), later in reprogramming (day 5 - day 7) or during the whole process (day 0 - day 7) in three independent reprogramming rounds, n=3 (except for TGFβ, n=2). Flow cytometry analysis at day 7 of SSEA1 and X-GFP percentages is shown. Data represented as mean +/− SD. Statistics (paired t-tests): where not specified = non-significant; * = p<0.05; ** = p<0.01; *** = p<0.001.

Article Snippet: The gRNA library used for the screening was the Mouse Improved Genome-wide Knockout CRISPR Library v2 (a gift from Kosuke Yusa, Addgene, #67988) , with 90,230 gRNAs targeting 18,424 genes (average of 5 gRNAs per gene).

Techniques: Infection, Genome Wide, Expressing, DNA Extraction, Amplification, Sequencing, Comparison, Software, CRISPR, Flow Cytometry, Biomarker Discovery

A genome-wide CRISPR knockout screen reveals molecular networks involved in reprogramming and X-chromosome reactivation. Related to . (A) Validation of knockout efficiency by flow cytometry. Flow cytometry analysis during 6 days of doxycycline treatment in the X-GFP iCas9 ESC line was done to measure the X-GFP percentage decay in cells containing a gRNA targeting the GFP gene. Gating shows the X-GFP+ population. (B) Percentage of gRNA representation in the plasmid library, infected ESCs and the 4 populations analyzed in two independent screening rounds: NPCs and day 10 reprogramming populations (non-pluripotent, early pluripotent, late pluripotent). Error bars represent SD. ( C ) gRNA abundance comparisons (related to D-G): NPCs to non-pluripotent, early pluripotent and late pluripotent populations. ( D ) Pathways related to common underrepresented genes (n=927 genes) in the three reprogramming populations compared to NPCs (WikiPathways Mouse 2019). For all comparisons, a RRA score < 0.05 and Log2FC < −0.75 (underrepresented) filtering was applied. ( E-G ) Representation of genes with negative Log2FC (underrepresented) vs −log10 RRA in the non-pluripotent (E), early pluripotent (F) and late pluripotent (G) populations compared to NPCs (RRA cutoff = 0.05, Log2FC cutoff = −0.75). ( H ) Pathways (WikiPathways Mouse 2019) related to underrepresented genes in the “early pluripotent vs non-pluripotent” comparison (activators of early pluripotency, n=1361 genes) (RRA score < 0.05 and Log2FC < −0.8 filtering was applied). ( I ) Pathways (WikiPathways Mouse 2019) related to overrepresented genes in the “early pluripotent vs non-pluripotent” comparison (repressors of early pluripotency, n=693 genes) (RRA score < 0.05 and Log2FC < −0.8 filtering was applied). ( J ) Representation of genes with positive Log2FC (overrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = 0.75) in the “early pluripotent vs non-pluripotent” comparison (repressors of early pluripotency). ( K ) Representation of genes with positive Log2FC (overrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = 0.75) in the “late pluripotent vs early pluripotent” comparison (repressors of late pluripotency, X-reactivation). ( L ) Pathways (WikiPathways Mouse 2019) related to overrepresented genes in the “late pluripotent vs early pluripotent” comparison (repressors of late pluripotency, X-reactivation, n=839 genes) (RRA score < 0.05 and Log2FC < −0.8 filtering was applied).

Journal: bioRxiv

Article Title: The Interferon γ Pathway Enhances Pluripotency and X-Chromosome Reactivation in iPSC reprogramming

doi: 10.1101/2023.07.31.551297

Figure Lengend Snippet: A genome-wide CRISPR knockout screen reveals molecular networks involved in reprogramming and X-chromosome reactivation. Related to . (A) Validation of knockout efficiency by flow cytometry. Flow cytometry analysis during 6 days of doxycycline treatment in the X-GFP iCas9 ESC line was done to measure the X-GFP percentage decay in cells containing a gRNA targeting the GFP gene. Gating shows the X-GFP+ population. (B) Percentage of gRNA representation in the plasmid library, infected ESCs and the 4 populations analyzed in two independent screening rounds: NPCs and day 10 reprogramming populations (non-pluripotent, early pluripotent, late pluripotent). Error bars represent SD. ( C ) gRNA abundance comparisons (related to D-G): NPCs to non-pluripotent, early pluripotent and late pluripotent populations. ( D ) Pathways related to common underrepresented genes (n=927 genes) in the three reprogramming populations compared to NPCs (WikiPathways Mouse 2019). For all comparisons, a RRA score < 0.05 and Log2FC < −0.75 (underrepresented) filtering was applied. ( E-G ) Representation of genes with negative Log2FC (underrepresented) vs −log10 RRA in the non-pluripotent (E), early pluripotent (F) and late pluripotent (G) populations compared to NPCs (RRA cutoff = 0.05, Log2FC cutoff = −0.75). ( H ) Pathways (WikiPathways Mouse 2019) related to underrepresented genes in the “early pluripotent vs non-pluripotent” comparison (activators of early pluripotency, n=1361 genes) (RRA score < 0.05 and Log2FC < −0.8 filtering was applied). ( I ) Pathways (WikiPathways Mouse 2019) related to overrepresented genes in the “early pluripotent vs non-pluripotent” comparison (repressors of early pluripotency, n=693 genes) (RRA score < 0.05 and Log2FC < −0.8 filtering was applied). ( J ) Representation of genes with positive Log2FC (overrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = 0.75) in the “early pluripotent vs non-pluripotent” comparison (repressors of early pluripotency). ( K ) Representation of genes with positive Log2FC (overrepresented) vs −log10 RRA (RRA cutoff = 0.05, Log2FC cutoff = 0.75) in the “late pluripotent vs early pluripotent” comparison (repressors of late pluripotency, X-reactivation). ( L ) Pathways (WikiPathways Mouse 2019) related to overrepresented genes in the “late pluripotent vs early pluripotent” comparison (repressors of late pluripotency, X-reactivation, n=839 genes) (RRA score < 0.05 and Log2FC < −0.8 filtering was applied).

Article Snippet: The gRNA library used for the screening was the Mouse Improved Genome-wide Knockout CRISPR Library v2 (a gift from Kosuke Yusa, Addgene, #67988) , with 90,230 gRNAs targeting 18,424 genes (average of 5 gRNAs per gene).

Techniques: Genome Wide, CRISPR, Knock-Out, Biomarker Discovery, Flow Cytometry, Plasmid Preparation, Infection, Comparison

Mouse embryonic fibroblasts (MEF) stably expressing Flag-Cas9-EGFP were transduced with a lentiviral CRISPR-library. Cells were treated three times with PMT(C1165S)DTa and surviving cells grown. Genomic DNA was extracted, inserted sgRNA amplified and sequenced.

Journal: bioRxiv

Article Title: Genome wide CRISPR screen for Pasteurella multocida toxin (PMT) binding proteins reveals LDL Receptor Related Protein1 (LRP1) as crucial cellular receptor

doi: 10.1101/2022.08.04.502755

Figure Lengend Snippet: Mouse embryonic fibroblasts (MEF) stably expressing Flag-Cas9-EGFP were transduced with a lentiviral CRISPR-library. Cells were treated three times with PMT(C1165S)DTa and surviving cells grown. Genomic DNA was extracted, inserted sgRNA amplified and sequenced.

Article Snippet: We utilized a well-functioning and validate genome-wide mouse lentiviral CRISPR guide RNA library v2 (Addgene).

Techniques: Stable Transfection, Expressing, Transduction, CRISPR, Amplification

The volcano plot shows gene expression changes between cells treated with lethal PMT-DTa chimera and those only transduced with the CRISPR library. All reads were mapped locally using BWA-MEM [ ,6], then quantified with featureCounts [4], and finally fold changes between the condition were calculated by DESeq2 [7] (see galaxy history). The volcano plot was drawn with the bioinfokit toolkit [8]. Significantly enriched genes, having a positive fold change above 0.584 and a p-value lower or equal 5%, are shown in blue. The significance thresholds are marked by gray-dotted lines. The ten most significant genes are highlighted with their name. Non-significant genes are colored in gray.

Journal: bioRxiv

Article Title: Genome wide CRISPR screen for Pasteurella multocida toxin (PMT) binding proteins reveals LDL Receptor Related Protein1 (LRP1) as crucial cellular receptor

doi: 10.1101/2022.08.04.502755

Figure Lengend Snippet: The volcano plot shows gene expression changes between cells treated with lethal PMT-DTa chimera and those only transduced with the CRISPR library. All reads were mapped locally using BWA-MEM [ ,6], then quantified with featureCounts [4], and finally fold changes between the condition were calculated by DESeq2 [7] (see galaxy history). The volcano plot was drawn with the bioinfokit toolkit [8]. Significantly enriched genes, having a positive fold change above 0.584 and a p-value lower or equal 5%, are shown in blue. The significance thresholds are marked by gray-dotted lines. The ten most significant genes are highlighted with their name. Non-significant genes are colored in gray.

Article Snippet: We utilized a well-functioning and validate genome-wide mouse lentiviral CRISPR guide RNA library v2 (Addgene).

Techniques: Gene Expression, Transduction, CRISPR

CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy

Journal: Molecular Therapy Oncolytics

Article Title: Advancements in CRISPR screens for the development of cancer immunotherapy strategies

doi: 10.1016/j.omto.2023.100733

Figure Lengend Snippet: CRISPR screens in T cells to develop advanced T-cell-based products for cancer immunotherapy

Article Snippet: Mouse , CD4 + T cells , loss of function , library pMSCV-U6gRNA(lib)-PGKpuroT2ABFP (Addgene: #104861) , retrovirus transduction , expression of IRF4, XBP1, or GATA3 , Pparg and Bhlhe40 , PPARG (peroxisome proliferator activated receptor gamma) and BHLHE40 (basic-helix-loop-helix protein 40) , PPARG and BHLHE40 are crucial to TH2 gene regulation and differentiation. Genes regulating TH2 activation and genes regulating TH2 differentiation are highly overlapped. , Henriksson et al. (2019) .

Techniques: CRISPR, Transduction, Selection, Expressing, Activation Assay, Retroviral, Genome Wide, Knock-Out, In Vitro, Activity Assay, Electroporation, Membrane, Adoptive Transfer Assay, Transgenic Assay, Infection, In Vivo, Migration, Biomarker Discovery, Immunofluorescence, Staining, Flow Cytometry